Literature DB >> 11100896

Von Willebrand's factor mediates the adherence of human tumoral cells to human endothelial cells and ticlopidine interferes with this effect.

M Morganti1, A Carpi, B Amo-Takyi, A Sagripanti, A Nicolini, R Giardino, C Mittermayer.   

Abstract

The aim of this study was to explore whether von Willebrand's factor (vWF) plays a role in the adhesion of human colon tumor cells to human endothelial cells in our coculture system. Cell colony density was evaluated basally (endothelial plus colon tumor cells) and following the addition of: purified vWF, vWF plus vWF-blocking antibodies, antibodies against various integrins and adhesion molecules (alpha2 b integrin, beta1 integrin, beta3 integrin, intercellular adhesion molecule-I, intercellular adhesion molecule-II, vitronectin receptor CD61 CD51, laminin alpha6/beta4 receptor), and various drugs inhibiting the hemostatic system (ticlopidine, heparin, acetyl salicylic acid [ASA], defibrotide, indobuphen, dipyridamole, sulfinpyrazone). Furthermore, vWF concentration was measured in the supernatant fluid of the coculture system basally and following the addition of the above-listed drugs. Cell colony density (as measured by light absorption) increased by 33% following the addition of vWF and returned to a value similar to the basal level with antibodies against vWF, while it did not change significantly following the addition of antibodies against the other integrins or adhesion molecules tested. The same parameter was reduced by 35% following the addition of ticlopidine, while it showed a smaller or no change with the other drugs tested. Similarly, vWF concentration in the cell coculture supernatant showed the greatest reduction (from 0.22 to 0.11 mg/mL) following the addition of ticlopidine. These data suggest that vWF mediates the adherence of human tumor cells to human endothelial cells and that ticlopidine interferes with this effect.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11100896     DOI: 10.1016/s0753-3322(00)00006-8

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  12 in total

1.  New wrinkle between cancer and blood coagulation: metastasis and cleavage of von Willebrand factor by ADAM28.

Authors:  Stanley Zucker; Jian Cao
Journal:  J Natl Cancer Inst       Date:  2012-05-25       Impact factor: 13.506

2.  Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer.

Authors:  Ignasio Gil-Bazo; Ignacio Gil Bazo; Victoria Catalán Goni; Victoria Catalán González; Alvaro Alonso Gutiérrez; Javier Rodríguez Rodríguez; José Antonio Páramo Fernández; Juan de la Cámara Gómez; José Luis Hernández Lizoain; Jesús García-Foncillas López
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

3.  Plasma von Willebrand factor level as a prognostic indicator of patients with metastatic colorectal carcinoma.

Authors:  Wei-Shu Wang; Jen-Kou Lin; Tzu-Chen Lin; Tzeon-Jye Chiou; Jin-Hwang Liu; Chueh-Chuan Yen; Po-Min Chen
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

4.  Hyperglycemia-induced oxidative stress promotes tumor metastasis by upregulating vWF expression in endothelial cells through the transcription factor GATA1.

Authors:  Han-Seok Jeong; Da-Hye Lee; Seung-Hoon Kim; Chang-Han Lee; Hyun Mu Shin; Hang-Rae Kim; Chung-Hyun Cho
Journal:  Oncogene       Date:  2022-01-29       Impact factor: 8.756

5.  Functional assessment of von Willebrand factor expression by cancer cells of non-endothelial origin.

Authors:  Anahita Mojiri; Konstantin Stoletov; Maria Areli Lorenzana Carrillo; Lian Willetts; Saket Jain; Roseline Godbout; Paul Jurasz; Consolato M Sergi; David D Eisenstat; John D Lewis; Nadia Jahroudi
Journal:  Oncotarget       Date:  2017-02-21

Review 6.  Deciphering the Role of the Coagulation Cascade and Autophagy in Cancer-Related Thrombosis and Metastasis.

Authors:  Charlotte Nicole Hill; Maria Paz Hernández-Cáceres; Catalina Asencio; Begoña Torres; Benjamin Solis; Gareth I Owen
Journal:  Front Oncol       Date:  2020-12-07       Impact factor: 6.244

7.  Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.

Authors:  Yingmiao Liu; Mark D Starr; Anuradha Bulusu; Herbert Pang; Nan Soon Wong; Wanda Honeycutt; Anthony Amara; Herbert I Hurwitz; Andrew B Nixon
Journal:  Cancer Med       Date:  2013-03-06       Impact factor: 4.452

8.  Predicting pathogenic genes for primary myelofibrosis based on a system‑network approach.

Authors:  Shu-Cai Xu; Peng Ning
Journal:  Mol Med Rep       Date:  2017-10-20       Impact factor: 2.952

9.  von Willebrand factor rescued by miR-24 inhibition facilitates the proliferation and migration of osteosarcoma cells in vitro.

Authors:  Ling Liu; Jun Pan; Huan Wang; Zhenni Ma; Jie Yin; Feng Yuan; Quanwen Yuan; Lu Zhou; Xiaofeng Liu; Yu Zhang; Zhaohua Bao; Huilin Yang; Jing Ling
Journal:  Biosci Rep       Date:  2018-11-15       Impact factor: 3.840

10.  Von Willebrand factor, ADAMTS13 and mortality in dialysis patients.

Authors:  Gurbey Ocak; Mark Roest; Marianne C Verhaar; Maarten B Rookmaaker; Peter J Blankestijn; Willem Jan W Bos; Rob Fijnheer; Nathalie C Péquériaux; Friedo W Dekker
Journal:  BMC Nephrol       Date:  2021-06-16       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.